Results 1 to 10 of about 37,235 (219)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome

Haematologica, 2021
FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in acute myeloid leukemia (AML) is associated with poor prognosis. We hypothesized that quizartinib, a selective and potent FLT3 inhibitor, with azacitidine (AZA) or low-dose ...
Mahesh Swaminathan, Hagop M Kantarjian, Mark Levis, Veronica Guerra, Gautam Borthakur, Yesid Alvarado, Courtney D DiNardo, Tapan Kadia, Guillermo Garcia-Manero, Maro Ohanian, Naval Daver, Marina Konopleva, Naveen Pemmaraju, Alessandra Ferrajoli, Michael Andreeff, Nitin Jain, Zeev Estrov, Elias J Jabbour, William G Wierda, Sherry Pierce, Maria Rhona Pinsoy, Lianchun Xiao, Farhad Ravandi, Jorge E Cortes   +23 more
doaj   +1 more source

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

HemaSphere, 2019
. AML with RUNX1-RUNX1T1 fusion is a WHO entity with a favorable outcome following intensive chemotherapy. The absence of RUNX1-RUNX1T1 transcripts in remission defines complete molecular response and correlates with a superior survival.
Alexander Höllein, Niroshan Nadarajah, Manja Meggendorfer, Sabine Jeromin, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +6 more
doaj   +1 more source

P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

HemaSphere, 2022
A. Bazinet, E. Jabbour, H. Kantarjian, K. Chien, C. DiNardo, M. Ohanian, N. Daver, R. Kanagal-Shamanna, T. Kadia, K. Takahashi, L. Masarova, N. Short, Y. Alvarado, P. Thompson, G. Montalban-Bravo, M. Yilmaz, F. Ravandi, M. Konopleva, M. Andreeff, S. Kornblau, N. Pemmaraju, D. Hammond, H. Schneider, B. Mirabella, G. Garcia-Manero   +24 more
doaj   +1 more source

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

HemaSphere, 2022
S. Venugopal, H. kantarjian, A. Maiti, N. Short, G. Montalban-Bravo, Y. Alvarado, K. S. Chien, R. Kanagal-Shamanna, N. Pemmaraju, N. Daver, T. Kadia, G. Borthakur, E. Jabbour, G. Garcia-Manero   +13 more
doaj   +1 more source

Acute pro-B-cell lymphoblastic leukemia evolving from myelodysplastic neoplasm post-cytotoxic therapy: a case report

Haematologica
Not available.
Jana Wobst, Marietta Truger, Constance Baer, Manja Meggendorfer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach   +6 more
doaj   +1 more source

S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY

HemaSphere, 2022
M. Yilmaz, M. Muftuoglu, H. Kantarjian, C. DiNardo, T. Kadia, G. Borthakur, N. Pemmaraju, N. Short, Y. Alvarado, A. Maiti, L. Masarova, G. Montalban Bravo, S. Loghavi, K. Patel, S. Kornblau, E. Jabbour, G. Garcia-Manero, M. Andreeff, N. Daver   +18 more
doaj   +1 more source

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

HemaSphere, 2022
K. Chien, K. Kim, Z. Li, R. Kanagal Shamanna, F. Ong, G. Montalban Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero   +16 more
doaj   +1 more source

S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY

HemaSphere, 2022
N. Short, H. Kantarjian, M. Konopleva, N. Jain, F. Ravandi, X. Huang, W. Macaron, W. Wierda, G. Borthakur, T. Kadia, K. Sasaki, G. Issa, G. Montalban-Bravo, Y. Alvarado, G. Garcia-Manero, C. Dinardo, J. Thankachan, R. Delumpa, E. Mayor, W. Deen, A. Milton, J. Rivera, L. Waller, C. Loiselle, R. Garris, E. Jabbour   +25 more
doaj   +1 more source

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics

Haematologica, 2013
The significance of flow cytometry indicating myelodysplasia without proof of myelodysplasia by cytomorphology remains to be clarified. We evaluated follow-up analyses in 142 patients analyzed in parallel by flow cytometry, cytomorphology and ...
Wolfgang Kern, Claudia Haferlach, Susanne Schnittger, Tamara Alpermann, Torsten Haferlach   +4 more
doaj   +1 more source

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

HemaSphere, 2022
N. Short, H. Kantarjian, F. Ravandi, M. Yilmaz, T. Kadia, P. Thompson, X. Huang, M. Konopleva, A. Ferrajoli, N. Jain, K. Sasaki, Y. Alvarado, G. Borthakur, C. Dinardo, M. Ohanian, W. Macaron, S. Kornblau, M. Zhao, M. Kwari, C. Loiselle, R. Delumpa, A. Milton, J. Rivera, S. Lewis, R. Garris, E. Jabbour   +25 more
doaj   +1 more source